9 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Advanced adrenocortical carcinoma is adrenal cortex cancer that has spread to distant organs or cannot be removed. The standard is mitotane with etoposide, doxorubicin and cisplatin, established by the FIRM-ACT trial in 304 patients; limited spread is treated locally, hormone excess with steroid-blocking drugs, and immunotherapy helps a minority.
Metastatic adrenocortical carcinoma is often a double problem: a fast-growing cancer and, in the majority of patients, uncontrolled cortisol or androgen excess that itself causes muscle wasting, infections, thrombosis and diabetes. Mitotane, which destroys adrenocortical cells and blocks steroid synthesis, is the backbone of treatment and is started at diagnosis in all patients, with adrenal enzyme inhibitors such as metyrapone or osilodrostat added when cortisol needs to fall quickly; the glucocorticoid receptor antagonist relacorilant was tested with pembrolizumab in a phase 1 trial in cortisol-secreting tumours that finished in 2023 with 15 patients and has posted no results on the registry. Tumours with a low burden of disease and a slow course can be treated with mitotane alone or with resection, ablation or stereotactic radiotherapy of metastases, and the ESE/ENSAT guideline advises against debulking surgery unless most of the disease can be removed.
FIRM-ACT (New England Journal of Medicine 2012), a randomised phase 3 trial, compared mitotane with etoposide, doxorubicin and cisplatin (EDP-M) against mitotane with streptozocin in 304 patients: EDP-M produced more responses (23.2 against 9.2 percent) and longer progression-free survival (5.0 against 2.1 months) without a significant difference in overall survival (median 14.8 against 12.0 months, with crossover allowed), and it has been the first-line standard since. Nothing has matched it in second line. Gemcitabine with capecitabine gives modest disease control; the multikinase inhibitor cabozantinib kept 13 of 18 patients free of progression at four months in a phase 2 trial (median progression-free survival 6 months); pembrolizumab produced responses in 23 percent of 39 patients in one phase 2 trial and in 2 of 14 in another, in two of six mismatch-repair-deficient tumours but also in seven microsatellite-stable ones, and most carcinomas are immunologically cold, in part because cortisol suppresses immunity, so trials now combine checkpoint inhibitors with cortisol blockade or with cabozantinib. The steroidogenic enzyme CYP11B1 is a target for radiolabelled tracers and the IGF-1 receptor inhibitor linsitinib, aimed at the IGF-2 pathway that drives many tumours, did not lengthen survival over placebo in its phase 3 trial of 139 patients. Five-year survival in stage IV disease is usually under 20 percent, and referral to an ENSAT centre and to trials is recommended for every patient.
| Setting | Approach | Guideline |
|---|---|---|
| All patients | Mitotane from diagnosis with glucocorticoid replacement; adrenal enzyme inhibitors (metyrapone, osilodrostat, ketoconazole) for cortisol excess; thromboprophylaxis and infection vigilance. | not mapped |
| Low-burden, indolent disease | Mitotane alone, with resection, thermal ablation or stereotactic radiotherapy of limited metastases. | not mapped |
| High-burden or progressive disease, first line | Etoposide, doxorubicin and cisplatin with mitotane (EDP-M, FIRM-ACT). | not mapped |
| After EDP-M | Gemcitabine with capecitabine; cabozantinib; pembrolizumab, especially for mismatch-repair-deficient tumours; streptozocin-mitotane; clinical trials. | not mapped |
| Trials | Cabozantinib with pembrolizumab or cemiplimab (phase 2 trials recruiting); relacorilant with pembrolizumab for cortisol-secreting tumours (phase 1 trial completed in 2023, no results posted); radiolabelled CYP11B tracers. | not mapped |